This content is restricted.
Brief
On September 20, 2024, the Federal Cartel Office initiated a review of Edwards Lifesciences' acquisition of JenaValve Technology Inc. The investigation revealed that neither national nor EU thresholds for mandatory notification were met due to insufficient domestic presence of JenaValve in Germany at the time of the proposed takeover. Consequently, further review under the transaction value threshold was not warranted, and the Federal Cartel Office discontinued its proceedings.
Highlights content goes here...
This content is restricted.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
